EUVIMEDEUVIMED entdecken
Crossref

Voriconazole plus flucytosine is not superior to amphotericin B deoxycholate plus flucytosine as an induction regimen for cryptococcal meningitis treatment

Handan Zhao, Yanqiu Lu, Shan Li, Jiangying Qin, Miaomiao Xu, Hui Ye, Zongxing Yang, Jianfeng Rao, Guochun Chen, Feifei Su, Zhiliang Hu, Lijun Xu iD

Mycoses · 2024

DOI: 10.1111/myc.13674 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Mycoses, 2024. Verfasst von Handan Zhao und 11 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. Hauptthemen laut MEDLINE: Flucytosine, Meningitis, Cryptococcal, Amphotericin B, Deoxycholic Acid. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: North China Pharmaceutical Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The efficacy and side effects of voriconazole plus 5‐flucytosine (Vori + 5‐FC) versus amphotericin B deoxycholate plus 5‐flucytosine (AmBd + 5‐FC) as an induction treatment for cryptococcal meningitis are unknown.

Methods

Forty‐seven patients treated with Vori + 5‐FC and 92 patients treated with AmBd + 5‐FC were included in the current study after propensity score matching (PSM) at a ratio of 1:2. Two‐week laboratory test results and 90‐day mortality were compared between the two groups.

Results

After 2 weeks of induction treatment, the CSF Cryptococcus sterile culture rate was 57.1% in the Vori + 5‐FC group and 76.5% in the AmBd + 5‐FC group ( p = .026). No difference was found in the normalization of CSF indicators (glucose, total protein, intracranial pressure and India ink sterile rate) between the two groups. Both the Vori + 5FC regimen and AmBd + 5‐FC regimen obviously decreased haemoglobin concentrations, platelet counts and serum potassium levels (all p ≤ .010). Notably, the Vori + 5FC regimen did not influence serum creatinine levels ( p = .263), while AmBd + 5FC increased serum creatinine levels ( p = .019) after 2‐week induction treatment. The Vori + 5‐FC group and AmBd + 5‐FC group had similar 90‐day cumulative survival rates (89.9% vs. 87.8%, p = .926).

Conclusion

The Vori + 5‐FC regimen was associated with low 2‐week CSF sterile culture and was not superior to AmBd + 5‐FC as induction therapy in terms of the 90‐day cumulative survival rate of CM patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FlucytosineMeningitis, CryptococcalAmphotericin BDeoxycholic AcidHumansAntifungal AgentsVoriconazoleCreatinineDrug Therapy, CombinationFluconazoleDrug Combinations

Stichwörter der Autor:innen

amphotericin Bcryptococcal meningitisefficacyside effectvoriconazole

Substanzen

amphotericin B, deoxycholate drug combinationFlucytosineAntifungal AgentsVoriconazoleCreatinineFluconazoleAmphotericin BDeoxycholic AcidDrug Combinations

Autor:innen und Institutionen

  • National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
  • The State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
  • Chongqing Public Health Medical Center, Southwest University Public Health Hospital, Chongqing, China.
  • Department of Infectious Diseases, The Ninth Hospital of Nanchang, Nanchang, China.
  • Department of Infectious Disease, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, China.
  • Department of Infectious Diseases, Wenzhou Central Hospital, Wenzhou, China.

ORCID-Profile: Lijun Xu

Förderung

  • North China Pharmaceutical Company

Zitieren

APA

Zhao, H., Lu, Y., Li, S., Qin, J., Xu, M., Ye, H., Yang, Z., Rao, J., Chen, G., Su, F., Hu, Z., & Xu, L. (2024). Voriconazole plus flucytosine is not superior to amphotericin B deoxycholate plus flucytosine as an induction regimen for cryptococcal meningitis treatment. Mycoses. https://doi.org/10.1111/myc.13674

Vancouver

Zhao H, Lu Y, Li S, Qin J, Xu M, Ye H, et al. Voriconazole plus flucytosine is not superior to amphotericin B deoxycholate plus flucytosine as an induction regimen for cryptococcal meningitis treatment. Mycoses. 2024. doi:10.1111/myc.13674

BibTeX
@article{Zhao2024,
  author = {Zhao, Handan and Lu, Yanqiu and Li, Shan and Qin, Jiangying and Xu, Miaomiao and Ye, Hui and Yang, Zongxing and Rao, Jianfeng and Chen, Guochun and Su, Feifei and Hu, Zhiliang and Xu, Lijun},
  title = {Voriconazole plus flucytosine is not superior to amphotericin B deoxycholate plus flucytosine as an induction regimen for cryptococcal meningitis treatment},
  journal = {Mycoses},
  year = {2024},
  doi = {10.1111/myc.13674}
}
Kostenlos starten →